Why the study?
Electroconvulsive therapy is effective and relatively safe, but associated major adverse cardiac events and deaths have been reported, prompting the use of surrogate parameters to measure cardiovascular safety.
Troponin time courses may serve as surrogate parameters to measure the cardiovascular safety of electroconvulsive therapy and detect subclinical pathological processes.
May inform troponin monitoring during electroconvulsive therapy; leaves open prospective validation before clinical adoption.
Electroconvulsive therapy (ECT) is an effective and established therapeutic tool for various severe psychiatric diseases. It is known to be relatively safe with no absolute contraindications to its use according to the American Psychiatric Association. However, major adverse cardiac events and deaths in association with ECT have been reported [1]. Complications may include ECG abnormalities or takotsubo myopathy. One way of measuring the cardiovascular safety of ECT is the use of surrogate parameters that may indicate subclinical pathological processes.
No takes yet. Share an insight, caveat, or question.
Schnellbächer et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: